213 related articles for article (PubMed ID: 33860826)
1. Preoperative prediction of pathologic grade of HCC on gadobenate dimeglumine-enhanced dynamic MRI.
Rong D; Liu W; Kuang S; Xie S; Chen Z; Chen F; Xie Q; Luo Q; He B; Zhang Y; Deng Y; Yang H; Chen S; Wang J
Eur Radiol; 2021 Oct; 31(10):7584-7593. PubMed ID: 33860826
[TBL] [Abstract][Full Text] [Related]
2. Quantitative information from gadobenate dimeglumine-enhanced MRI can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study.
Ding F; Huang M; Ren P; Zhang J; Lin Z; Sun Y; Liang C; Zhao X
Eur Radiol; 2024 Apr; 34(4):2445-2456. PubMed ID: 37691080
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI.
Choi SH; Lee JM; Yu NC; Suh KS; Jang JJ; Kim SH; Choi BI
AJR Am J Roentgenol; 2008 Aug; 191(2):529-36. PubMed ID: 18647927
[TBL] [Abstract][Full Text] [Related]
4. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
Dioguardi Burgio M; Picone D; Cabibbo G; Midiri M; Lagalla R; Brancatelli G
Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma.
Allen BC; Ho LM; Jaffe TA; Miller CM; Mazurowski MA; Bashir MR
AJR Am J Roentgenol; 2018 Jun; 210(6):1266-1272. PubMed ID: 29629800
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular Carcinoma: Retrospective Evaluation of the Correlation Between Gadobenate Dimeglumine-Enhanced Magnetic Resonance Imaging and Pathologic Grade.
Huang X; Xiao Z; Zhang Y; Lin N; Xiong M; Huang X; Chen Q; Cao D
J Comput Assist Tomogr; 2018; 42(3):365-372. PubMed ID: 29369947
[TBL] [Abstract][Full Text] [Related]
7. Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine.
Stocker D; Hectors S; Bane O; Vietti-Violi N; Said D; Kennedy P; Cuevas J; Cunha GM; Sirlin CB; Fowler KJ; Lewis S; Taouli B
Eur Radiol; 2021 Dec; 31(12):9306-9315. PubMed ID: 34043055
[TBL] [Abstract][Full Text] [Related]
8. Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience.
Park Y; Kim SH; Kim SH; Jeon YH; Lee J; Kim MJ; Choi D; Lee WJ; Kim H; Koo JH; Lim HK
Korean J Radiol; 2010; 11(4):433-40. PubMed ID: 20592927
[TBL] [Abstract][Full Text] [Related]
9. The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria.
Zhang Y; Tang W; Xie S; Chen J; Zhang L; Rong D; Kuang S; He B; Wang J
Eur Radiol; 2021 Oct; 31(10):7715-7724. PubMed ID: 33782766
[TBL] [Abstract][Full Text] [Related]
10. [The predictive value of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid enhanced MRI imaging features combined with quantitative parameters for the pathologic grading of hepatocellular carcinoma].
Hu MJ; Yu YX; Fan YF; Jiang YM; Hu S; Wang XM; Hu CH
Zhonghua Yi Xue Za Zhi; 2020 May; 100(17):1299-1304. PubMed ID: 32375436
[No Abstract] [Full Text] [Related]
11. Comparison of Gadobenate-Enhanced MRI and Gadoxetate-Enhanced MRI for Hepatocellular Carcinoma Detection Using LI-RADS Version 2018: A Prospective Intraindividual Randomized Study.
Rong D; He B; Tang W; Xie S; Kuang S; Grazioli L; Hussain SM; Yang Y; Wang J
AJR Am J Roentgenol; 2022 Apr; 218(4):687-698. PubMed ID: 34817191
[No Abstract] [Full Text] [Related]
12. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
[TBL] [Abstract][Full Text] [Related]
13. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
[TBL] [Abstract][Full Text] [Related]
14. Quantitative parameters obtained from gadobenate dimeglumine-enhanced MRI at the hepatobiliary phase can predict post-hepatectomy liver failure and overall survival in patients with hepatocellular carcinoma.
Cai S; Lin X; Sun Y; Lin Z; Wang X; Lin N; Zhao X
Eur J Radiol; 2022 Sep; 154():110449. PubMed ID: 35901599
[TBL] [Abstract][Full Text] [Related]
15. Effect of increasing the flip angle during the hepatocyte phase of gadobenate dimeglumine-enhanced 1.5T MRI in cirrhotic patients with hepatocellular carcinoma.
Lee EJ; Kim DJ; Cho ES; Kim KA
J Magn Reson Imaging; 2016 Mar; 43(3):713-9. PubMed ID: 26290384
[TBL] [Abstract][Full Text] [Related]
16. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
Jeon TY; Kim SH; Lee WJ; Lim HK
Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
[TBL] [Abstract][Full Text] [Related]
17. Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine.
Khouri Chalouhi C; Vernuccio F; Rini F; Duca P; Tuscano B; Brancatelli G; Vanzulli A
Eur Radiol; 2019 Jun; 29(6):3090-3099. PubMed ID: 30547205
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
[TBL] [Abstract][Full Text] [Related]
19. Comparison of superparamagnetic iron oxide-enhanced and gadobenate dimeglumine-enhanced dynamic MRI for detection of small hepatocellular carcinomas.
Kim YK; Kim CS; Lee YH; Kwak HS; Lee JM
AJR Am J Roentgenol; 2004 May; 182(5):1217-23. PubMed ID: 15100122
[TBL] [Abstract][Full Text] [Related]
20. Does the hepatocellular phase of gadobenate dimeglumine help to differentiate hepatocellular carcinoma in cirrhotic patients according to histological grade?
Tahir B; Sandrasegaran K; Ramaswamy R; Bertrand K; Mhapsekar R; Akisik FM; Saxena R
Clin Radiol; 2011 Sep; 66(9):845-52. PubMed ID: 21771548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
